Progesterone, a key hormone that fluctuates throughout the menstrual cycle and other reproductive phases, plays an important role in brain function, mood, stress responses, and cognition. For people with PMDD, this review brings together evidence that helps explain why symptoms occur and highlights a promising treatment approach.
One of the most relevant findings covered here is from a clinical trial testing ulipristal acetate, a medication that blocks progesterone from acting on its receptors in the brain. In that trial, people with PMDD who took this medication saw a 41% improvement in their symptom scores, compared with 22% for those on placebo. Half of the treatment group experienced complete or partial remission of premenstrual symptoms, with the strongest improvements seen in depression and irritability. Brain imaging studies of this treatment suggest it may help the brain's emotion-regulation circuits work more effectively during the premenstrual phase.
The review also explains a concept called the "hormone sensitivity hypothesis" — the idea that people with PMDD don't necessarily have abnormal hormone levels, but their brains respond differently to normal hormonal fluctuations. Allopregnanolone, a natural breakdown product of progesterone that affects the brain's calming GABA system, appears to have a complex relationship with mood: it can be calming at very low or very high levels but may worsen mood at the moderate levels typically seen during the luteal phase. This may help explain why premenstrual symptoms emerge during the second half of the cycle.
While these findings are encouraging, the authors note that much of the research is still in early stages, with small study sizes and a need for more carefully designed trials. They emphasize that the specific effects of progesterone are difficult to separate from those of estrogen in most real-world situations, and that different types of synthetic progestins used in contraceptives and hormone therapy may affect the brain in different ways.
Key findings
- In a proof-of-concept RCT, the selective progesterone receptor modulator ulipristal acetate (5 mg/day) reduced PMDD psychological symptoms by 41% vs 22% for placebo (mean difference −18%), with 50% achieving complete or partial remission
- Pharmacological administration of 400 mg progesterone in healthy women increased amygdala reactivity during emotion processing but decreased amygdala activity during a memory task, suggesting a dose-dependent effect potentially mediated by allopregnanolone
- Allopregnanolone (ALLO) shows an inverted U-shaped relationship with mood: anxiolytic at low and high doses, but potentially anxiogenic at moderate (luteal-phase) levels, analogous to benzodiazepine paradoxical effects
- SPRM treatment in PMDD patients enhanced dorsal anterior cingulate cortex and dorsomedial prefrontal cortex reactivity during aggressive responses, suggesting improved top-down emotion regulation, while brain structure remained unchanged
- National cohort data from Danish registries showed a dose-dependent association between parenteral levonorgestrel (LNG-IUD) administration and incident depression
- Progesterone and progestins demonstrate neuroprotective effects in preclinical stroke models, and oral progestin-only contraceptive use does not increase cardiovascular risk, unlike combined oral contraceptives
Methods, briefly
Narrative review synthesizing preclinical animal studies, pharmacological neuroimaging experiments, randomized controlled trials, national registry-based cohort studies, and prior systematic reviews and meta-analyses. No formal systematic search protocol or meta-analytic pooling was performed. The review covers literature on puberty, menstrual cycle, pregnancy, perimenopause, hormonal contraceptives, and menopausal hormone therapy.
Limitations to keep in mind
- Most reviewed pharmacological studies on progesterone effects in humans are based on single studies with small sample sizes, limiting generalizability
- In menstrual cycle, pregnancy, HC, and MHT studies, the effects of progestagens cannot be disentangled from the effects of estrogens
- This is a narrative rather than systematic review, so the literature search and inclusion criteria are not standardized
- Most preclinical neuroprotection studies were performed in male animals, and confirmation of findings in females is largely lacking
- Cross-sectional comparisons of HC users are prone to selection bias and may reflect individual sensitivity rather than pharmacological differences between progestins
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.